Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gerresheimer AGGRRMF +2.83%58 EV-to-EBITDA is 10.47 as of Aug. 07, 2026, which is 2% above its 10-year median of 10.26. GuruFocus rates GRRMF with a GF Score™ of 58/100 and a GF Value™ of $191.08 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Gerresheimer AG ranks better than 67.77% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gerresheimer AG's enterprise value is $3,377 Mil.
Gerresheimer AG's EBITDA for the trailing twelve months (TTM) ended in Nov. 2025 was $323 Mil. Therefore, Gerresheimer AG's EV-to-EBITDA for today is 10.47.
The historical rank and industry rank for Gerresheimer AG's EV-to-EBITDA or its related term are showing as below:
GRRMF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.41 Med: 10.26 Max: 14.7
Current: 10.21
During the past 13 years, the highest EV-to-EBITDA of Gerresheimer AG was 14.70. The lowest was 7.41. And the median was 10.26.
GRRMF's EV-to-EBITDA is ranked better than 67.77% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.645
vs GRRMF: 10.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Gerresheimer AG (OTCPK:GRRMF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gerresheimer AG's PE Ratio (TTM) for today is calculated as:
Gerresheimer AG's share price for today is $31.68.
Gerresheimer AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.675.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Gerresheimer AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Gerresheimer AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gerresheimer AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gerresheimer AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gerresheimer AG's EV-to-EBITDA falls into.
Gerresheimer AG's current Enterprise Value is $3,377 Mil.
Gerresheimer AG's EBITDA for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $323 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gerresheimer AG (GRRMF) has a EV-to-EBITDA of 10.47 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gerresheimer AG. This is near median its historical median of 10.26. Over the past decade, Gerresheimer AG's EV-to-EBITDA has ranged from 7.41 to 14.70. According to the industry distribution chart, Gerresheimer AG ranks #165 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 32.2%.
Is Gerresheimer AG's EV-to-EBITDA too high?
Gerresheimer AG's current EV-to-EBITDA of 10.47 is near median its 10-year median of 10.26. Over the past 10 years, this metric has ranged from a low of 7.41 to a high of 14.70. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.65. Gerresheimer AG's value of 10.47 is 28.5% below this industry median. Based on the distribution chart, Gerresheimer AG ranks #165 out of 512 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gerresheimer AG has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gerresheimer AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gerresheimer AG ranks #165 out of 512 companies for EV-to-EBITDA. This puts Gerresheimer AG in the upper half of its industry. The industry median EV-to-EBITDA is 14.65. Gerresheimer AG's value of 10.47 is 28.5% below this benchmark. Historically, Gerresheimer AG's own EV-to-EBITDA has ranged from 7.41 to 14.70 over the past decade. While the company's 10-year median is 10.26 vs. the industry median of 14.65, Gerresheimer AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.65, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gerresheimer AG's current EV-to-EBITDA of 10.47 is 28.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gerresheimer AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gerresheimer AG's current EV-to-EBITDA is 10.47, which is near median its own 10-year median of 10.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gerresheimer AG stock overvalued right now?
Based on GuruFocus' analysis, Gerresheimer AG (GRRMF) is currently considered Possible Value Trap. The stock's GF Value™ is $191.08, compared to a current price of $31.68 — trading 83.4% below its estimated fair value. The current EV-to-EBITDA is 10.47, which is near median its 10-year median of 10.26 and 28.5% below the Medical Devices & Instruments industry median of 14.65. Gerresheimer AG's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Gerresheimer AG (GRRMF), the current EV-to-EBITDA is 10.47 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gerresheimer AG (GRRMF) Overvalued in 2026?
Based on GuruFocus' analysis, Gerresheimer AG stock appears to be undervalued.
The current stock price of $31.68 is trading 83.4% below its estimated GF Value™ of $191.08.
GuruFocus considers Gerresheimer AG to be Possible Value Trap.
Key valuation signals for GRRMF:
EV-to-EBITDA: 10.47 (near median its 10-year median of 10.26)
GF Value™: $191.08 vs. price of $31.68 (83.4% below fair value)
Industry Position: 28.5% below the Medical Devices & Instruments median (#165 of 512)
No single metric tells the full story. See the GRRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
58GF Score
Get the complete analysis for GRRMF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRRMF has been successfully added to your 
